Company Overview
IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MSense, a multi probe system for the treatment of multiple and larger tumors. The company serves hospitals, interventional radiological centers, ambulatory centers, and private clinics. IceCure Medical Ltd was incorporated in 2006 and is headquartered in Caesarea, Israel.
Recent Developments
- Dec 2025 Revenue of $3.38M (+2.7% YoY); net profit $-15.06M.
- Trailing 12 Months Year-on-year growth — revenue +72.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 3.1%, profit CAGR 3.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 3.08% |
| 1 Year: | 72.80% |
Compounded Profit Growth
| 5 Years: | 3.77% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -91.23% |
| 6 Months: | -87.98% |
| 3 Months: | -39.29% |
| 1 Month: | -28.25% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)31.89 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 93.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ICCM IceCure Medical Ltd PHARMA | 2.21 | -0.33 | $7.57M | 0.00% | - | - | 3.08% | 3.77% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 725.00K | 525.00K | 850.00K | 1.28M | 911.00K |
| Cost of Revenue | - | 507.00K | 394.00K | 573.00K | 679.00K | 616.00K |
| Gross Profit | - | 218.00K | 131.00K | 277.00K | 600.00K | 295.00K |
| Operating Expenses | - | 3.88M | 3.52M | 4.11M | 4.82M | 4.54M |
| Operating Income | - | -3.66M | -3.38M | -3.84M | -4.22M | -4.25M |
| EBITDA | - | -3.57M | -3.32M | -3.76M | -4.14M | -4.18M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | -3.59M | -3.36M | -3.86M | -4.25M | -4.27M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | - | -3.59M | -3.36M | -3.86M | -4.25M | -4.27M |
| Diluted EPS | - | -1.80 | - | - | - | -1.80 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 3.08M | 3.23M | 3.29M | 3.38M |
| Cost of Revenue | 1.64M | 1.93M | 1.84M | 2.15M |
| Gross Profit | 1.45M | 1.30M | 1.45M | 1.23M |
| Operating Expenses | 18.18M | 16.88M | 17.15M | 16.32M |
| Operating Income | -16.74M | -15.58M | -15.70M | -15.09M |
| EBITDA | -16.49M | -15.25M | -15.36M | -14.80M |
| Interest Expense | - | - | - | - |
| Pretax Income | -16.98M | -14.65M | -15.32M | -15.06M |
| Tax Provision | - | - | - | - |
| Net Income | -16.98M | -14.65M | -15.32M | -15.06M |
| Diluted EPS | -13.54 | -9.60 | -8.83 | -7.20 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 30.19M | 16.41M | 12.58M | 13.89M |
| Current Assets | - | 28.13M | 14.18M | 10.75M | 12.61M |
| Cash & Equivalents | - | 23.66M | 10.53M | 7.56M | 8.90M |
| Inventory | - | 2.86M | 2.27M | 1.99M | 2.62M |
| Receivables | - | 78.00K | 103.00K | 221.00K | 331.00K |
| Total Liabilities | - | 4.77M | 4.25M | 5.67M | 4.84M |
| Current Liabilities | - | 4.34M | 3.87M | 5.51M | 4.82M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 597.00K | 599.00K | 459.00K | 217.00K |
| Total Equity | - | 25.42M | 12.16M | 6.90M | 9.05M |
| Shares Outstanding | - | 1.55M | 1.55M | 1.92M | 2.44M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -14.29M | -12.55M | -12.56M | -14.57M |
| Investing Cash Flow | - | -891.00K | -684.00K | 446.00K | -36.00K |
| Financing Cash Flow | - | 13.58M | 83.00K | 9.19M | 15.83M |
| Capital Expenditure | - | -891.00K | -480.00K | -71.00K | -36.00K |
| Free Cash Flow | - | -15.18M | -13.03M | -12.63M | -14.61M |
| Net Change in Cash | - | -1.61M | -13.15M | -2.93M | 1.22M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 46.8% | 40.3% | 44.1% | 36.3% |
| Operating Margin % | -542.6% | -482.4% | -476.9% | -446.7% |
| Net Margin % | -550.3% | -453.8% | -465.5% | -445.6% |
| ROE % | -66.8% | -120.5% | -222.0% | -166.4% |
| ROCE % | -64.7% | -124.2% | -222.3% | -166.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC | 1.02% | 34.88K | $68.37K |
| 2 | Scientech Research LLC | 0.95% | 32.70K | $64.08K |
| 3 | Gunderson Capital Management LLC | 0.58% | 20.00K | $39.20K |
| 4 | UBS Group AG | 0.50% | 17.09K | $33.50K |
| 5 | HRT Financial LP | 0.44% | 15.15K | $29.70K |
| 6 | JPMORGAN CHASE & CO | 0.17% | 5.95K | $11.66K |
| 7 | Morgan Stanley | 0.13% | 4.33K | $8.49K |
| 8 | Kingdom Financial Group LLC. | 0.02% | 533 | $1.04K |
| 9 | SBI Securities Co., Ltd. | 0.01% | 451 | $883 |
| 10 | Avion Wealth | 0.01% | 195 | $382 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ICCM
ICCM Stock On Track For Best Day In Nearly 5 Years — What’s Driving The 200% Rally? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxPR0NTTG43NUFZdUsyb0tPNnNnWUpjZWRuMXQ2eTE4QVNZR09OZ0xObXU4OUlrSVpfRDBwdW9BUzJwQVB0TVdaV1FaUGJGdzFzd0lrdk0wbnFWREhuWmpFaDl2NjhDNmoyb19Gd0NaRHZYX2FfR3h6MFVGYXl2TENhVTA1QmVQU3UwUkdZRz…
When Will IceCure Medical Ltd (NASDAQ:ICCM) Turn A Profit? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxNejkwTXhIaUtyUFV6N0FrejdMN1JZTFhxaUtKOTdtTjJka2F3MG9oWVpEMDVjdlpsUmdHemRGVER0dXlJdGM1aE9BSmlHSDRpTGZHUW5pbnpHM3diWVZ1bnJ2SVBaR1EzZzhjaE5HRVdCMm13dDlhbTRuX0V3MndmbEtPNA?oc=5" targe…
IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance - PR Newswire
<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxNS0ZVb2NPS1JLN3IxX21LNFllQ1BKZHlIbFdOYmpDVDNnbldkOHNrWVROZFNKRnZuRUNxWjdxRWtETzlCNTBYNGRhZ1J0REU1ME9WdkxuREJoaEtpLWdsR1lfeDlYMGkwYXZBYmlWWVlFSHVKX3lWZUp6ZGg1dEtuaG5ka01kSGxKaE1HVC…
ICCM Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5FRHlnM1RxZmdJNnhpN0dCakxxU0FpUE1wTWU0VUYwbWR3Z3l4S1phT3ZxaEJsaVdNVHR1amx5WEhYbm9pcEtncjRELU9YSjluUFBFVzJucnJWOHpadUdVUGdTclVxeUNaY0J5eXEwZUU0ZUpZMlBfOFVn?oc=5" target="_blank">ICC…
IceCure's ProSense Is First and Only for Low-Risk Breast Cancer With FDA Marketing Authorization - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOYThnTDVlbmpXSkVQX3phVS1FQ0VtRldlUjNFU1VFR2hSX21fczZhQnJVWnhxR0ZuQlV2a2NWMmkwdXpLbVNzdGw0eTJpOFFnVWpNSkhram1LNEE4VlJJLVJPaTk3cTltcjBBTVFORng2OW9TSE0xTnlCY1I5eGJ6bzFEaWpqR05tbDFTSU…
IceCure Stock Surges After 70% ProSense Install Increase - Icecure Medical (NASDAQ:ICCM) - Benzinga
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNSXFPOFRHSkY1YTE2a29wdXdDRTgzbGJkUjdLQ04tZ05ZZmhZN3B0VTltd1pTY0o1Ym9WSnp0ckJZYTNsQTFpZjl6MmI2alBxZEZfVmN1S1lkdUc2RWxPOW9WY2dIdFQ1NC1sNGRXMFF5ZU9xMWdRbUVXRzZrTEZTNi0zX19ab1ZTWG9idk…
ICCM — Frequently Asked Questions
What is the current share price of IceCure Medical Ltd (ICCM)?
As of 2026-09-19 21:16 PDT, IceCure Medical Ltd (ICCM) trades at $2.21 on NasdaqCM. Its 52-week range is $2.13 to $35.70.
What is the market capitalisation of ICCM?
IceCure Medical Ltd (ICCM) has a market capitalisation of $7.57M on NasdaqCM.
What is the P/E ratio of ICCM?
ICCM trades at a trailing price-to-earnings (P/E) ratio of -0.33. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.71.
Is ICCM a good stock to buy?
This page provides a data-driven analysis of IceCure Medical Ltd (ICCM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.